Related references
Note: Only part of the references are listed.Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
Jacob Sterling et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2023)
Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Satoshi Ida et al.
HEART FAILURE REVIEWS (2021)
Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction
Marco Trevisan et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease
Filipe Ferrari et al.
ANNALS OF PHARMACOTHERAPY (2021)
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting
Federico Rea et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57)
Yasushi Ishigaki et al.
DIABETES THERAPY (2021)
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Chelsea Baker et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2021)
Heart Disease and Stroke Statistics-2021 Update A Report From the American Heart Association
Salim S. Virani et al.
CIRCULATION (2021)
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts
Marta Baviera et al.
DIABETES OBESITY & METABOLISM (2021)
Liraglutide protects against lethal renal ischemia-reperfusion injury by inhibiting high-mobility group box 1 nuclear-cytoplasmic translocation and release
Yakun Li et al.
PHARMACOLOGICAL RESEARCH (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
Kazushi Uneda et al.
SCIENTIFIC REPORTS (2021)
A Bibliometrics Analysis of Metformin Development From 1980 to 2019
Yanjun Song et al.
FRONTIERS IN PHARMACOLOGY (2021)
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Dario Giugliano et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA
HoJin Shin et al.
DIABETES CARE (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis
Weiyun Qian et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock et al.
LANCET (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes
Yaqin Zhang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study
Spela Zerovnik et al.
BMJ OPEN (2021)
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
Ian J. Neeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols
Claudia Penna et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
Valerie D. Heuvelman et al.
CARDIOVASCULAR RESEARCH (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Effects of glucagon-tike peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Fabio Marsico et al.
EUROPEAN HEART JOURNAL (2020)
Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
Bjorn Pasternak et al.
DIABETES CARE (2020)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
Steven P. Marso et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
Sanjay Kalra et al.
DIABETES THERAPY (2020)
Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
Enrico Longato et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients
Dimitrios Patoulias et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Jonathan M. Wilson et al.
DIABETES OBESITY & METABOLISM (2020)
Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Kyu Yeon Hur et al.
DIABETES & METABOLISM JOURNAL (2020)
Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial
Weiqing Wang et al.
DIABETES OBESITY & METABOLISM (2019)
Glucagon-like peptide-1 receptor action in the vasculature
Malak Almutairi et al.
PEPTIDES (2019)
Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults
Sridharan Raghavan et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Epidemiology of Diabetes Mellitus and Cardiovascular Disease
Diana Glovaci et al.
CURRENT CARDIOLOGY REPORTS (2019)
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
FRONTIERS IN ENDOCRINOLOGY (2019)
Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area
Manel Mata-Cases et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Lawrence A. Leiter et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
Richard E. Pratley et al.
DIABETES OBESITY & METABOLISM (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2019)
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
Vjera Nincevic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The Global Burden of Cardiovascular Diseases and Risk Factors 2020 and Beyond
George A. Mensah et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis
Solomon Nuhoho et al.
DIABETES THERAPY (2019)
Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months
Fernando Moreno Obregon et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?
Kenichi Katsurada et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035 A Policy Statement From the American Heart Association
Sandra B. Dunbar et al.
CIRCULATION (2018)
Should Metformin Be First-line Therapy for Patients With Type 2 Diabetes and Chronic Kidney Disease? Informed Patients Should Decide
Chester B. Good et al.
JAMA INTERNAL MEDICINE (2018)
Recent updates on GLP-1 agonists: Current advancements & challenges
Dilip Sharma et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Brad P. Dieter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca2+ channels
Reshma Ramracheya et al.
PHYSIOLOGICAL REPORTS (2018)
Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial
Mark M. Smits et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
Evgenia Gourgari et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
Michael Feher et al.
DIABETES THERAPY (2017)
Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
Michael Feher et al.
DIABETES THERAPY (2017)
Diabetes and cardiovascular events in high-risk patients: Insights from a multicenter registry in a middle-income country
Beatriz D. Schaan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
James Crane et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Current understanding of metformin effect on the control of hyperglycemia in diabetes
Hongying An et al.
JOURNAL OF ENDOCRINOLOGY (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
Amrita Ostawal et al.
DIABETES THERAPY (2016)
Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
Amrita Ostawal et al.
DIABETES THERAPY (2016)
Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy
Scott R. Drab
CURRENT DIABETES REVIEWS (2016)
Is diabetes a hypercoagulable state? A critical appraisal
Fulvio Pomero et al.
ACTA DIABETOLOGICA (2015)
Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways
Lili Shi et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
Caroline S. Fox et al.
DIABETES CARE (2015)
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
Feng Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System
Jennifer E. Richard et al.
PLOS ONE (2015)
Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
Andrew E. Hogan et al.
DIABETOLOGIA (2014)
Changes in Diabetes-Related Complications in the United States, 1990-2010
Edward W. Gregg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment
Zhenhua Dong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
The central GLP-1: implications for food and drug reward
Karolina P. Skibicka
FRONTIERS IN NEUROSCIENCE (2013)
Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells
Li Ding et al.
ACTA PHARMACOLOGICA SINICA (2012)
Oxidative Stress and Diabetic Complications
Ferdinando Giacco et al.
CIRCULATION RESEARCH (2010)
Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
Paolo Tessari et al.
DIABETES (2010)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Importance of weight management in Type 2 diabetes: Review with meta-analysis of clinical studies
JW Anderson et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2003)
Share Paper
